{"@id":"https://bioecon.ru/technology/fetal-sparing-antibody-engineering/","@type":"Technology","cluster":"therapeutics-platforms","formats":{"html":"https://en.bioecon.ru/technology/fetal-sparing-antibody-engineering/","json":"https://en.bioecon.ru/api/v1/technology/fetal-sparing-antibody-engineering/index.json"},"id":"fetal-sparing-antibody-engineering","industries":["pharma","biomanufacturing"],"lang":"en","links":{"industries":["https://bioecon.ru/industries/pharma/","https://bioecon.ru/industries/biomanufacturing/"],"suppliers":["https://bioecon.ru/companies/novartis/","https://bioecon.ru/companies/genmab/","https://bioecon.ru/companies/jiangsu-hengrui-medicine/","https://bioecon.ru/companies/daiichi-sankyo/","https://bioecon.ru/companies/johnson-johnson/","https://bioecon.ru/companies/altos-labs/","https://bioecon.ru/companies/vland-biotech/","https://bioecon.ru/companies/tsingke-biotechnology/","https://bioecon.ru/companies/e-square-environment-engineering-coltd/","https://bioecon.ru/companies/isomorphic-labs/"]},"maturity":7,"name":"Fetal-Sparing Antibody Engineering","regions":["ch","eu","us","cn"],"risk":"medium","section":"technology","sector":"health-biomedicine","sources":[{"date":"2026-11-22","entity":"Swiss Biotech Directory 2026","kind":"vendor","urls":["https://www.swissbiotech.org/directory/"]}],"stages":[{"n":1,"title":"FcRn binding abrogation"},{"n":2,"title":"Syncytiotrophoblast transcytosis assay"},{"n":3,"title":"Placental cotyledon perfusion"},{"n":4,"title":"Maternal PK and efficacy validation"}],"summary":"Engineered Fc domains with selectively abolished neonatal Fc receptor (FcRn) transcytosis across human syncytiotrophoblasts, enabling therapeutic treatment of severe maternal autoimmune diseases during pregnancy without drug transfer to the fetus.","url":"/technology/fetal-sparing-antibody-engineering/","verified":"2026-11-22"}